dr. mohler on overuse of adt in prostate cancer and nccn guidelines
Published 8 years ago • 1.1K plays • Length 1:25Download video MP4
Download video MP3
Similar videos
-
1:37
dr. james mohler discusses androgen-deprivation therapy for prostate cancer
-
1:10
dr. mohler on levels of adrenal androgens in prostate cancer
-
4:12
optimal adt for patients with prostate cancer and cv history
-
1:29
dr. mohler on guidelines for recording family history in prostate cancer
-
1:08
dr. mohler on need for genetic counselors for early detection of prostate cancer
-
1:31
dr. mohler on recommendations for genetic testing in prostate cancer
-
6:14
intermittent versus continuous androgen-deprivation therapy in prostate cancer
-
1:22
dr. james mohler discusses prostate cancer trial endpoints
-
2:07
dr. mohler on improving the efficacy of abiraterone
-
5:59
challenges associated with adt for prostate cancer
-
6:40
considerations for initiating adt in prostate cancer
-
6:24
age, exercise, and adt for prostate cancer
-
5:35
prostate cancer: which guidelines
-
1:07
dr. abdenour nabid on shorter duration of adt in prostate cancer
-
2:38
dr. james mohler on androgen signaling and prostate growth
-
3:13
dr. james mohler describes advances in the field of prostate cancer
-
3:50
considering adt’s role in advanced prostate cancer
-
1:24
dr. tward on abbreviated course adt for prostate cancer
-
5:04
effects of adt on morbidity and mortality